|本期目录/Table of Contents|

[1]崔永辉.莫沙必利治疗便秘型肠易激综合征重叠功能性消化不良临床研究[J].慢性病学杂志,2013,(11):823-825.
　CUI Yong-hui.Clinical study of mosapride in treating constipation type of irritable bowel syndrome overlapping with functional dyspepsia[J].,2013,(11):823-825.
点击复制

莫沙必利治疗便秘型肠易激综合征重叠功能性消化不良临床研究(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2013年11期
页码:
823-825
栏目:
论著
出版日期:
2013-11-30

文章信息/Info

Title:
Clinical study of mosapride in treating constipation type of irritable bowel syndrome overlapping with functional dyspepsia
作者:
崔永辉
商丘市第一人民医院消化内科,河南 商丘 476100
Author(s):
CUI Yong-hui
Department of Gastroenterology,The First People's Hospital of Shangqiu City,Shangqiu,Henan 476100,China
关键词:
莫沙必利;  便秘型肠易激综合征;  功能性消化不良;  疗效
Keywords:
Mosapride;  Constipation type of Irritable Bowel Syndrome(IBS);  Functional Dyspepsia(FD);  Clinical efficiency
分类号:
R574.4
DOI:
-
摘要:
目的 探讨莫沙必利对便秘型肠易激综合征重叠功能性消化不良患者治疗的临床疗效。方法 选取商丘市第一人民医院在2011年12月至2012年12月期间收治的80例便秘型肠易激综合征重叠功能性消化不良患者,随机分为对照组和观察组,对照组采用肠激宁治疗,观察组采用莫沙必利进行治疗,治疗4周后比较两组患者的临床疗效及临床症状积分。结果 治疗后,观察组总有效率(90%)明显高于对照组总有效率(72.5%),两组间差异有统计学意义(χ2=4.114 2,P<0.05); 且观察组各临床症状积分均明显低于对照组,差异具有统计学意义(t=2.021 7,P<0.05; t=1.992 8,P<0.05; t=2.007 2,P<0.05; t=2.050 5,P<0.05); 观察组治疗后各临床症状积分均较治疗前明显降低,差异有统计学意义(t=3.783 4,P<0.01; t=2.859 2,P<0.01; t=3.018 0,P<0.01; t=3.292 4,P<0.01)。结论 莫沙必利对便秘型肠易激综合征重叠功能性消化不良治疗的临床疗效明显,具有一定的临床意义。
Abstract:
Objective To explore the clinical efficacy of Mosapride on patients with constipation type of Irritable Bowel Syndrome(IBS)overlapping with Functional Dyspepsia(FD). Methods 80 patients with constipation type of IBS overlapping with FD were selected from the First People's Hospital Of Shangqiu,from December 2011 to December 2012.They were randomly assigned into control group which received intestinal stress treatment or observer group which received Mosapride.4 weeks after treatments,clinical effectiveness and clinical symptom score were collected and compared between two groups. Results After treatment,effective rate in observer group was 90% which was statistically significant higher than 72.5% in control group(χ2=4.114 2,P<0.05).Clinical symptom score in observer group was significantly lower than in control group(t=2.021 7,P<0.05; t=1.992 8,P<0.05; t=2.007 2,P<0.05; t=2.050 5,P<0.05).Clinical symptom score after treatment in observer group was significantly lower than before treatment(t=3.783 4,P<0.01; t=2.859 2,P<0.01; t=3.018 0,P<0.01; t=3.292 4,P<0.01). Conclusions Mosapride has a clear clinical effect on patients who have constipation type of IBS overlapping with FD.It's very important to clinical treatment.

参考文献/References:

[1] 沈曼茹,颜美珠,陈炜,等.莫沙必利治疗便秘型肠易激综合征重叠功能性消化不良临床研究[J].临床消化病杂志,2013,25(1):10-12.
[2] Kanazawa M,Watanabe S,Tana C,et al.Effect of 5-HT(4)receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndromo[J].Neurogastroenterol Motil,2011,23:754-e332.
[3] 秦丽杨,张秀峰,蒋挽澜.莫沙必利治疗便秘型肠易激综合征的研究[J].中国伤残医学,2011,19(2):67.
[4] 龙文醒,钟毅.肠激宁治疗功能性消化不良重叠便秘型肠易激综合征30例疗效观察[J].云南中医中药杂志,2013,34(5):44-45.
[5] 胡静.莫沙必利联合黛力新治疗功能性消化不良临床疗效观察[J].当代医学,2013,19(6):127-128.
[6] 王琼芬.莫沙必利联合黛力新治疗功能性消化不良60例临床观察[J].中国卫生产业,2012,9(1):48-49.
[7] 张焕乐.美常安联合莫沙必利分散片治疗便秘型肠易激综合征的临床研究[J].中国医学创新,2013,10(15):59-60.
[8] 韩荛.益生菌配伍黛力新治疗肠易激综合征的安全性及疗效分析[J].中国医学创新,2012,9(26):16-17.
[9] 田圣威.盐酸伊托必利治疗功能性消化不良重叠便秘型肠易激综合征疗效观察[J].药物与临床,2010,17(25):63-65.
[10] Mearin F,Balboa A.Post-infectious functional gastrointestinal disorders:from the acute episode to chronicity[J].Gastroenterol Hepatol,2011,34(6):415.
[11] 刘方旭,许乐.枳术宽中胶囊治疗功能性消化不良及抑郁症状疗效及安全性多中心、开放、随机对照研究[J].世界中医药,2012,7(6):484-485.
[12] 陈春永,郑永臻,朱迪盈.健脾补肾中药联合培菲康治疗腹泻型肠易激综合征44例[J].世界中医药,2008,3(3):163.

备注/Memo

备注/Memo:
作者简介:崔永辉,硕士,主治医师,主要从事消化系统疾病研究工作 通讯作者:崔永辉,E-mail:183705142@qq.com
更新日期/Last Update: 2013-11-30